USPTO Examiner STEVENS MARK V - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18602981PHARMACEUTICAL CAPSULES COMPRISING LUMATEPERONE MONO-TOSYLATEMarch 2024September 2024Allow610NoNo
18572144FREEZE-DRIED LOADED AEROGEL PARTICLES WITH BIOCIDAL PROPERTIESDecember 2023April 2025Allow1520YesNo
18512722COMBINATION TREATMENT FOR ANTIBIOTIC RESISTANT INFECTIONSNovember 2023July 2024Allow820NoNo
18511751COMBINATION TREATMENT FOR ANTIBIOTIC RESISTANT INFECTIONSNovember 2023November 2024Abandon1200NoNo
18504345PHARMACEUTICAL CAPSULE COMPOSITIONS COMPRISING LUMATEPERONE MONO-TOSYLATENovember 2023May 2024Allow610NoNo
18478482METHODS OF TREATMENT COMPRISING ADMINISTERING LUMATEPERONE MONO-TOSYLATE CAPSULESSeptember 2023June 2025Allow2120NoNo
18367869VAGINAL FILMSSeptember 2023July 2025Allow2230NoNo
18449547PREPARATION OF OCCLUSIVE DRESSINGSAugust 2023January 2025Abandon1710NoNo
18225377COMPOSITION FOR TREATING OR PREVENTING SKIN PIGMENTATIONJuly 2023June 2025Allow2220NoNo
18331772COMPOSITION OF MATTER, SYSTEM, AND METHOD FOR ENHANCED MAGNESIUM UPTAKE, RETENTION, AND SYNERGISTIC ACTIONSJune 2023June 2024Allow1220NoNo
18324449OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONSMay 2023October 2023Allow511NoNo
18141112COMPOSITION FOR THE TREATMENT OF REFRACTORY PAINFUL INTERVERTEBRAL DISC RELATED DISORDERS AND METHOD FOR DELIVERY THEREOF TO TREAT THERETOApril 2023December 2023Allow710NoNo
18139434GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOFApril 2023December 2024Allow2011NoNo
18192432COMBINATION TREATMENT FOR ANTIBIOTIC RESISTANT INFECTIONSMarch 2023April 2025Abandon2541NoNo
18184270ABUSE-DETERRENT DOSAGE FORMS CONTAINING ESKETAMINEMarch 2023January 2024Allow1020YesNo
18109769PREPARATION OF OCCLUSIVE DRESSINGSFebruary 2023January 2025Abandon2310NoNo
18108940COMPOSITIONS AND METHODS FOR REMEDIATING CHEMICAL WARFARE AGENT EXPOSED SKINFebruary 2023December 2023Allow1020NoNo
18159756HYDROGEL MEMBRANE FOR ADHESION PREVENTIONJanuary 2023June 2025Allow2920NoNo
18154695PHARMACEUTICAL SPRAY COMPOSITION COMPRISING A VITAMIN D ANALOGUE AND CORTICOSTEROIDJanuary 2023March 2025Abandon2601NoNo
18150145LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTSJanuary 2023April 2024Abandon1530YesNo
17986828COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH OXIDATIVE STRESSNovember 2022March 2025Abandon2820NoNo
17983125POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOFNovember 2022March 2025Abandon2810NoNo
17948968INGESTIBLE MEDICAL DELIVERY DEVICESSeptember 2022January 2025Abandon2720NoNo
17820325COMPOSITION OF MATTER, SYSTEM, AND METHOD FOR ENHANCED MAGNESIUM UPTAKE, RETENTION, AND SYNERGISTIC ACTIONSAugust 2022March 2023Allow710NoNo
17885065COSMETIC COMPOSITIONSAugust 2022February 2024Allow1820NoNo
17812832NANOPARTICLE DELIVERY SYSTEMSJuly 2022June 2025Abandon3520NoNo
17861711Misoprostol Dispersible TabletJuly 2022February 2024Allow1920NoNo
17857442STABILIZED TACROLIMUS COMPOSITIONJuly 2022May 2025Allow3430NoNo
17853650Topical Compositions For Treating Skin AilmentsJune 2022November 2024Abandon2910NoNo
17849425OPHTHALMIC DRUG DELIVERYJune 2022October 2023Allow1510NoNo
17832918SCALP PROTECTION COMPOSITIONJune 2022April 2024Allow2310NoNo
17826069DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHODMay 2022November 2022Allow610NoNo
17826034DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHODMay 2022November 2022Allow510YesNo
17826042DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHODMay 2022December 2022Allow710NoNo
17826082DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHODMay 2022November 2022Allow610NoNo
17824516NOVEL POVIDONE-IODINE PHARMACEUTICAL PREPARATION AND USES THEREOFMay 2022November 2024Abandon2911NoNo
17714465Wound-Care Composition and Method of UseApril 2022December 2023Allow2010NoNo
17691989PROCESSES FOR PREPARING ARIMOCLOMOL CITRATE AND INTERMEDIATES THEREOFMarch 2022March 2023Allow1210NoNo
17803148PERFORMANCE ENHANCEMENT DELIVERY SYSTEMMarch 2022January 2024Abandon2310NoNo
17687364SELF-FUELED PARTICLES FOR PROPULSION THROUGH FLOWING AQUEOUS FLUIDSMarch 2022October 2024Allow3220NoNo
17674146MICRONUTIRENT AND PLANT EXTRACT COMPOSITION AND METHOD OF IMRPOVING BONE HEALTHFebruary 2022August 2022Allow510NoNo
17673651BIOIMPLANT WITH EVANESCENT COATING FILMFebruary 2022February 2024Allow2420YesNo
17589838PHARMACEUTICAL PREPARATIONS AND METHODS TO MANAGE WEIGHT AND TO MODULATE THE GUT MICROBIOTAJanuary 2022July 2024Abandon3020YesNo
17584691Dedifferentiated cell extract of Bletilla and method for whitening, anti-oxidation and anti-wrinkling applying the same, and cosmetic comprising the sameJanuary 2022March 2025Allow3730NoNo
17582516METHODS OF TREATMENT USING PHARMACEUTICAL CAPSULE COMPOSITIONS COMPRISING LUMATEPERONE MONO-TOSYLATEJanuary 2022July 2023Allow1810NoNo
17569715COSMETIC COMPOSITIONS AND METHODSJanuary 2022July 2023Allow1810NoNo
17647149METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDERJanuary 2022September 2023Allow2110NoNo
17565348METHODS AND COMPOSITIONS OF AQUEOUS HYPOBROMOUS ACID FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY CONDITIONSDecember 2021March 2024Abandon2610NoNo
17561198COMPOSITIONS AND METHODS FOR TREATING DISEASES OF THE NAILDecember 2021September 2023Allow2010NoNo
17559158IMMEDIATE RELEASE ABUSE-DETERRENT GRANULATED DOSAGE FORMSDecember 2021August 2022Allow810NoNo
17558179TRANSDERMAL PATCHES FOR HANGOVER MINIMIZATION AND/OR RECOCERY, AND/OR SLEEP IMPROVEMENTDecember 2021September 2024Allow3320NoNo
17549975Cosmetic Compositions Comprising Sucrose Esters And SolventsDecember 2021October 2024Allow3440NoNo
17548931ABUSE-DETERRENT DOSAGE FORMS CONTAINING ESKETAMINEDecember 2021September 2023Abandon2110NoNo
17546645POLYMER SYSTEM FOR OPHTHALMIC DRUG DELIVERYDecember 2021May 2025Allow4131NoNo
17545584OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONSDecember 2021June 2022Allow711YesNo
17542282METHODS FOR ENHANCED ROOT NODULATION IN LEGUMESDecember 2021August 2023Abandon2110NoNo
17540649BIOBASED, UV-CURABLE NAIL POLISH COMPOSITIONS AND RELATED METHODSDecember 2021September 2024Abandon3311NoNo
17527528Immediate Release Abuse-Deterrent Granulated Dosage FormsNovember 2021August 2023Allow2110NoNo
17609531SUNSCREEN MULTILAYER PARTICLENovember 2021March 2024Allow2820YesNo
17514388ANTIMICROBIAL POLYMER COMPOSITIONS, FIBERS, AND YARNSOctober 2021March 2024Allow2920NoNo
17507091OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONSOctober 2021December 2021Allow200YesNo
17481874OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONSSeptember 2021March 2022Allow520NoNo
17411835KIDNEY-TARGETING DRUG DELIVERY CARRIERAugust 2021June 2024Abandon3320NoNo
17346975AMORPHOUS CALCIUM CARBONATE FOR TREATING A LEUKEMIAJune 2021June 2023Abandon2510NoNo
17413567A STABLE CARDIOPLEGIC SOLUTION FOR CARDIAC SURGERYJune 2021January 2024Allow3220YesNo
17343649STABILIZED AND NO2-INHIBITED NITRIC OXIDE GENERATING GELS FOR INHALED NITRIC OXIDE THERAPYJune 2021April 2025Allow4621YesNo
17337649Amino Acid Derivatives and Their UsesJune 2021September 2023Allow2810NoNo
17337548METHOD AND COMPOSITION FOR SELECTIVE TREATMENT OF ANDROGEN RECEPTORSJune 2021January 2025Allow4430NoNo
17338248TOPICAL FORMULATION AND METHODS FOR PAIN RELIEFJune 2021October 2023Abandon2810NoNo
17336148COMPOSITIONS AND METHODS FOR IMPROVING THE APPEARANCE OF THE SKINJune 2021February 2025Allow4530YesNo
17335981TOPICAL COMPOSITION FOR USE IN THE TREATMENT OF BURNSJune 2021July 2023Abandon2610NoNo
17298440COMPOSITION FOR TREATING OR PREVENTING SKIN PIGMENTATIONMay 2021November 2023Abandon3010YesNo
17332417PHARMACEUTICAL CAPSULE COMPOSITIONS COMPRISING LUMATEPERONE MONO-TOSYLATEMay 2021February 2023Allow2110NoNo
17327724STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOFMay 2021November 2024Allow4240NoNo
17326507COMPOSITIONS AND METHODS FOR REMEDIATING CHEMICAL WARFARE AGENT EXPOSED SKINMay 2021June 2025Allow4971YesNo
17313613SKIN CARE COMPOSITIONS AND METHODSMay 2021May 2023Abandon2401NoNo
17244910METHODS OF TREATING DEGENERATIVE BONE CONDITIONSApril 2021November 2024Allow4330NoNo
17244552PATCH WITH DMSO IN ADHESIVE LAYERApril 2021June 2023Allow2630YesNo
17238278METHOD AND SYSTEM FOR DRUG DELIVERYApril 2021April 2023Allow2410NoNo
17234432PREPARATION OF OCCLUSIVE DRESSINGSApril 2021April 2023Abandon2410NoNo
17220479METHOD FOR TREATMENT OF A VIRAL-MEDIATED INFECTIOUS DISEASEApril 2021April 2023Allow2510YesNo
17219800COMPOSITIONS AND METHODS FOR STYLING THE HAIRMarch 2021April 2025Allow4840YesNo
17218628COOLING SPRAYMarch 2021April 2023Allow2420YesNo
17217320HOMEOPATHIC NASAL GEL, SWAB, AND SPRAY FORMULATIONSMarch 2021March 2023Abandon2410NoNo
17213561Therapeutic Detoxification Compositions and Methods of Making and Using SameMarch 2021September 2023Allow2910NoNo
17212380COMPOSITION FOR THE TREATMENT OF NAIL FUNGUSMarch 2021January 2025Allow4560YesNo
17211274OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONSMarch 2021September 2021Allow610YesNo
17194587TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHEMOKINE/CHEMOKINE RECEPTOR INHIBITORMarch 2021January 2024Abandon3420NoNo
17194832TOPICAL IMMUNOSENSITIZERS TO TREAT VIRAL AND FUNGAL INFECTIONSMarch 2021December 2023Allow3320YesNo
17273855IRON CHELATORS FOR TREATING AESTHETIC SKIN CONDITIONSMarch 2021April 2024Abandon3830NoNo
17187982FRAGRANCE MATERIALSMarch 2021August 2023Allow2920NoNo
17184713POROUS MEDICAL DEVICE AND METHODS OF USEFebruary 2021April 2024Allow3831NoNo
17183076EXTENDED-RANGE SPRAY APPLICATORFebruary 2021October 2023Allow3211NoNo
17175082OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONSFebruary 2021July 2021Allow520NoNo
17171399COSMETIC COMPOSITION COMPRISING EXOSOMES DERIVED FROM GALACTOMYCES AS ACTIVE INGREDIENTFebruary 2021October 2022Allow2110NoNo
17167265TRACE ELEMENTSFebruary 2021August 2024Allow4240YesNo
17166624Ozone Foam for Treating DermatitisFebruary 2021January 2024Abandon3620YesNo
17162118PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISMJanuary 2021June 2024Abandon4121NoNo
17157118BICARBONATE AS A POTENTIATOR FOR ANTIMICROBIAL AGENTSJanuary 2021May 2023Allow2810NoNo
17259732TOPICAL DETOMIDINE FORMULATIONSJanuary 2021April 2024Abandon3931NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner STEVENS, MARK V.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
6
Examiner Affirmed
5
(83.3%)
Examiner Reversed
1
(16.7%)
Reversal Percentile
26.2%
Lower than average

What This Means

With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
53
Allowed After Appeal Filing
8
(15.1%)
Not Allowed After Appeal Filing
45
(84.9%)
Filing Benefit Percentile
15.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner STEVENS, MARK V - Prosecution Strategy Guide

Executive Summary

Examiner STEVENS, MARK V works in Art Unit 1613 and has examined 805 patent applications in our dataset. With an allowance rate of 65.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 25 months.

Allowance Patterns

Examiner STEVENS, MARK V's allowance rate of 65.7% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by STEVENS, MARK V receive 2.29 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by STEVENS, MARK V is 25 months. This places the examiner in the 64% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +45.6% benefit to allowance rate for applications examined by STEVENS, MARK V. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 24.0% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 49.3% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 75.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 58% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 81.2% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 88.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 61.1% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 46% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.8% of allowed cases (in the 75% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.